152 related articles for article (PubMed ID: 25722197)
1. Combined effect of CYP2B6 and NAT2 genotype on plasma efavirenz exposure during rifampin-based antituberculosis therapy in the STRIDE study.
Luetkemeyer AF; Rosenkranz SL; Lu D; Grinsztejn B; Sanchez J; Ssemmanda M; Sanne I; McIlleron H; Havlir DV; Haas DW;
Clin Infect Dis; 2015 Jun; 60(12):1860-3. PubMed ID: 25722197
[TBL] [Abstract][Full Text] [Related]
2. Effects of rifampin-based antituberculosis therapy on plasma efavirenz concentrations in children vary by CYP2B6 genotype.
McIlleron HM; Schomaker M; Ren Y; Sinxadi P; Nuttall JJ; Gous H; Moultrie H; Eley B; Merry C; Smith P; Haas DW; Maartens G
AIDS; 2013 Jul; 27(12):1933-40. PubMed ID: 24180002
[TBL] [Abstract][Full Text] [Related]
3. Dependence of efavirenz- and rifampicin-isoniazid-based antituberculosis treatment drug-drug interaction on CYP2B6 and NAT2 genetic polymorphisms: ANRS 12154 study in Cambodia.
Bertrand J; Verstuyft C; Chou M; Borand L; Chea P; Nay KH; Blanc FX; Mentré F; Taburet AM;
J Infect Dis; 2014 Feb; 209(3):399-408. PubMed ID: 23990572
[TBL] [Abstract][Full Text] [Related]
4. Pharmacogenetic interactions of efavirenz or rifampin and isoniazid with levonorgestrel emergency contraception during treatment of HIV or tuberculosis.
Agyemang N; Scarsi KK; Baker P; Smeaton LM; Podany AT; Olefsky M; Woolley E; Barr E; Pham M; Mawlana S; Supparatpinyo K; Gatechompol S; Jalil EM; Gadama L; Badal-Faesen S; Van Schalkwyk M; Kayama C; Belaunzaran-Zamudio PF; Godfrey C; Cohn SE; Mngqibisa R; Haas DW;
Pharmacogenet Genomics; 2023 Aug; 33(6):126-135. PubMed ID: 37306344
[TBL] [Abstract][Full Text] [Related]
5. CYP2B6 genotype, but not rifampicin-based anti-TB cotreatments, explains variability in long-term efavirenz plasma exposure.
Mukonzo JK; Nanzigu S; Waako P; Ogwal-Okeng J; Gustafson LL; Aklillu E
Pharmacogenomics; 2014 Aug; 15(11):1423-35. PubMed ID: 25303294
[TBL] [Abstract][Full Text] [Related]
6. Long-term efavirenz pharmacokinetics is comparable between Tanzanian HIV and HIV/Tuberculosis patients with the same CYP2B6*6 genotype.
Kitabi EN; Minzi OMS; Mugusi S; Sasi P; Janabi M; Mugusi F; Bertilsson L; Burhenne J; Aklillu E
Sci Rep; 2018 Nov; 8(1):16316. PubMed ID: 30397233
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic and pharmacogenomic modelling of the CYP3A activity marker 4β-hydroxycholesterol during efavirenz treatment and efavirenz/rifampicin co-treatment.
Ngaimisi E; Minzi O; Mugusi S; Sasi P; Riedel KD; Suda A; Ueda N; Bakari M; Janabi M; Mugusi F; Bertilsson L; Burhenne J; Aklillu E; Diczfalusy U
J Antimicrob Chemother; 2014 Dec; 69(12):3311-9. PubMed ID: 25096076
[TBL] [Abstract][Full Text] [Related]
8. CYP2B6*6, CYP2B6*18, Body weight and sex are predictors of efavirenz pharmacokinetics and treatment response: population pharmacokinetic modeling in an HIV/AIDS and TB cohort in Zimbabwe.
Dhoro M; Zvada S; Ngara B; Nhachi C; Kadzirange G; Chonzi P; Masimirembwa C
BMC Pharmacol Toxicol; 2015 Mar; 16():4. PubMed ID: 25889207
[TBL] [Abstract][Full Text] [Related]
9. Pharmacogenetics of plasma efavirenz exposure in HIV-infected adults and children in South Africa.
Sinxadi PZ; Leger PD; McIlleron HM; Smith PJ; Dave JA; Levitt NS; Maartens G; Haas DW
Br J Clin Pharmacol; 2015 Jul; 80(1):146-56. PubMed ID: 25611810
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic drug monitoring and pharmacogenetic study of HIV-infected ethnic Chinese receiving efavirenz-containing antiretroviral therapy with or without rifampicin-based anti-tuberculous therapy.
Lee KY; Lin SW; Sun HY; Kuo CH; Tsai MS; Wu BR; Tang SY; Liu WC; Chang SY; Hung CC
PLoS One; 2014; 9(2):e88497. PubMed ID: 24551111
[TBL] [Abstract][Full Text] [Related]
11. Is there a need to increase the dose of efavirenz during concomitant rifampicin-based antituberculosis therapy in sub-Saharan Africa? The HIV-TB pharmagene study.
Habtewold A; Makonnen E; Amogne W; Yimer G; Aderaye G; Bertilsson L; Burhenne J; Aklillu E
Pharmacogenomics; 2015; 16(10):1047-64. PubMed ID: 25831219
[TBL] [Abstract][Full Text] [Related]
12. Impact of pharmacogenetic markers of CYP2B6, clinical factors, and drug-drug interaction on efavirenz concentrations in HIV/tuberculosis-coinfected patients.
Manosuthi W; Sukasem C; Lueangniyomkul A; Mankatitham W; Thongyen S; Nilkamhang S; Manosuthi S; Sungkanuparph S
Antimicrob Agents Chemother; 2013 Feb; 57(2):1019-24. PubMed ID: 23254426
[TBL] [Abstract][Full Text] [Related]
13. Population Pharmacokinetic Model Linking Plasma and Peripheral Blood Mononuclear Cell Concentrations of Efavirenz and Its Metabolite, 8-Hydroxy-Efavirenz, in HIV Patients.
Habtewold A; Aklillu E; Makonnen E; Yimer G; Bertilsson L; Burhenne J; Owen JS
Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28559276
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of efavirenz when co-administered with rifampin in TB/HIV co-infected patients: pharmacogenetic effect of CYP2B6 variation.
Kwara A; Lartey M; Sagoe KW; Xexemeku F; Kenu E; Oliver-Commey J; Boima V; Sagoe A; Boamah I; Greenblatt DJ; Court MH
J Clin Pharmacol; 2008 Sep; 48(9):1032-40. PubMed ID: 18728241
[TBL] [Abstract][Full Text] [Related]
15. Long-Term Effect of Rifampicin-Based Anti-TB Regimen Coadministration on the Pharmacokinetic Parameters of Efavirenz and 8-Hydroxy-Efavirenz in Ethiopian Patients.
Habtewold A; Aklillu E; Makonnen E; Amogne W; Yimer G; Aderaye G; Bertilsson L; Owen JS; Burhenne J
J Clin Pharmacol; 2016 Dec; 56(12):1538-1549. PubMed ID: 27125860
[TBL] [Abstract][Full Text] [Related]
16. Influence of efavirenz pharmacokinetics and pharmacogenetics on neuropsychological disorders in Ugandan HIV-positive patients with or without tuberculosis: a prospective cohort study.
Mukonzo JK; Okwera A; Nakasujja N; Luzze H; Sebuwufu D; Ogwal-Okeng J; Waako P; Gustafsson LL; Aklillu E
BMC Infect Dis; 2013 Jun; 13():261. PubMed ID: 23734829
[TBL] [Abstract][Full Text] [Related]
17. Isoniazid mediates the CYP2B6*6 genotype-dependent interaction between efavirenz and antituberculosis drug therapy through mechanism-based inactivation of CYP2A6.
Court MH; Almutairi FE; Greenblatt DJ; Hazarika S; Sheng H; Klein K; Zanger UM; Bourgea J; Patten CJ; Kwara A
Antimicrob Agents Chemother; 2014 Jul; 58(7):4145-52. PubMed ID: 24820076
[TBL] [Abstract][Full Text] [Related]
18. CYP2B6 genotype-based efavirenz dose recommendations during rifampicin-based antituberculosis cotreatment for a sub-Saharan Africa population.
Mukonzo JK; Bisaso RK; Ogwal-Okeng J; Gustafsson LL; Owen JS; Aklillu E
Pharmacogenomics; 2016 Apr; 17(6):603-13. PubMed ID: 27045425
[TBL] [Abstract][Full Text] [Related]
19. High efavirenz serum concentrations in TB/HIV-coinfected Ugandan adults with a CYP2B6 516 TT genotype on anti-TB treatment.
von Braun A; Castelnuovo B; Ledergerber B; Cusato J; Buzibye A; Kambugu A; Fehr J; Calcagno A; Lamorde M; Sekaggya-Wiltshire C
J Antimicrob Chemother; 2019 Jan; 74(1):135-138. PubMed ID: 30239753
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics and Drug-Drug Interactions of Isoniazid and Efavirenz in Pregnant Women Living With HIV in High TB Incidence Settings: Importance of Genotyping.
Gausi K; Wiesner L; Norman J; Wallis CL; Onyango-Makumbi C; Chipato T; Haas DW; Browning R; Chakhtoura N; Montepiedra G; Aaron L; McCarthy K; Bradford S; Vhembo T; Stranix-Chibanda L; Masheto GR; Violari A; Mmbaga BT; Aurpibul L; Bhosale R; Nevrekhar N; Rouzier V; Kabugho E; Mutambanengwe M; Chanaiwa V; Nyati M; Mhembere T; Tongprasert F; Hesseling A; Shin K; Zimmer B; Costello D; Jean-Philippe P; Sterling TR; Theron G; Weinberg A; Gupta A; Denti P;
Clin Pharmacol Ther; 2021 Apr; 109(4):1034-1044. PubMed ID: 32909316
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
